Answers are grounded in this paper and cite their sources.
Atopic dermatitis (AD) involving sensitive and/or visible hard-to-treat areas, including the head and neck, face, hands, feet, and genital regions, is associated with a significant psychosocial and clinical burden. AD involving these high-burden areas is commonly associated with diminished patient quality of life and a range of management challenges for patients and clinicians. There is a notable lack of epidemiological evidence investigating these regions, with experts highlighting that high-burden areas are poorly defined and under-studied. Evidence to inform clinical practice often comes from sub-analyses, and there is a clear need for more directed research into optimal treatment of high-burden regions. Advancing knowledge of AD pathophysiology has enabled a better understanding of the burden of disease and, along with it, a new generation of targeted therapies. Real-world evidence evaluating the safety and effectiveness of these systemic treatments is increasingly crucial for clinicians to understand and apply their impact when making decisions in routine clinical practice for patients with AD in high-burden areas. A panel of seven expert dermatologists convened for a series of virtual roundtable discussions, conducted on 18th February, 27th February, and 5th March 2026. Experts discussed a series of questions in a roundtable discussion based on pre-read literature provided before the discussion, focusing on unmet needs in high-burden AD, and emerging clinical data on biologic treatment. Discussion was moderated by the medical writer. This article presents excerpts from the expert roundtable discussion on high-burden areas in AD, covering understanding high-burden AD and its associated challenges, the current treatment landscape, and ongoing unmet needs. In particular, the expert roundtable discussion highlighted a need for consistent terminology, clear clinical guidance, and robust data on systemic management specific to AD affecting high-burden areas. Patient disease burden, unmet needs, access to systemic treatments, and emerging data informing potential individualised AD management were explored.
No takes yet. Share an insight, caveat, or question.
Chalmers et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: